[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351349-105":59,"doc-detail-351349-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","fatty-acid-oxidation-drives-acetyl-coa-dependent-h3k9ac-reprogramming-to-promote-adaptive-resistance-to-brafv600e-inhibition-in-thyroid-cancer","Fatty acid oxidation drives acetyl-CoA-dependent H3K9ac reprogramming to promote adaptive resistance to BRAFV600E inhibition in thyroid cancer","","BRAF-targeted therapy for thyroid cancer is limited by adaptive drug resistance to BRAFV600E inhibition (BRAFi). Integrated transcriptomic and metabolomic analyses show that BRAFi with vemurafenib markedly enhances fatty acid oxidation (FAO) in thyroid cancer cells. Pharmacological FAO blockade using thioridazine synergizes with BRAFi to suppress tumor growth in vitro, in vivo, and in patient-derived organoids. Mechanistically, increased PGC1α drives higher intracellular acetyl-CoA, reshaping H3K9 acetylation and epigenetically activating pro-survival RUNX1, whose expression links to worse prognosis and whose knockdown reduces malignancy phenotypes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/fatty-acid-oxidation-drives-acetyl-coa-dependent-h3k9ac-reprogramming-to-promote-adaptive-resistance-to-brafv600e-inhibition-in-thyroid-cancer/351349/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/fatty-acid-oxidation-drives-acetyl-coa-dependent-h3k9ac-reprogramming-to-promote-adaptive-resistance-to-brafv600e-inhibition-in-thyroid-cancer/351349.png","ImageObject",300,407,{"name":92,"@type":93},"WPS_1786070896","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does BRAFV600E inhibition influence fatty acid oxidation in thyroid cancer?","Question",{"text":112,"@type":113},"BRAFV600E inhibition with vemurafenib significantly enhances fatty acid oxidation (FAO) in thyroid cancer cells, as shown by integrated transcriptomic and metabolomic analyses.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What is the effect of pharmacologically inhibiting FAO during BRAFi treatment?",{"text":117,"@type":113},"FAO inhibition using thioridazine synergizes with BRAFV600E inhibition to suppress tumor growth in vitro, in vivo, and in patient-derived organoids.",{"name":119,"@type":110,"acceptedAnswer":120},"How does increased acetyl-CoA connect metabolism to epigenetic activation of resistance genes?",{"text":121,"@type":113},"The metabolic shift increases intracellular acetyl-CoA, which reprograms the histone H3K9 acetylation (H3K9ac) landscape and epigenetically activates pro-survival genes such as RUNX1.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351349,1790169400,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},549768072016,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","[www.nature.com/cddis](www.nature.com/cddis)  \nARTICLE OPEN   \nFatty acid oxidation drives acetyl-CoA-dependent H3K9acreprogramming to promote adaptive resistance to BRAFV600E inhibition in thyroid cancer  \nXumeng Wang 1,8, Jing Zhang 1,8, Jimeng Yuan1, Liping Wen 1, Tianxing Ying2,3, Zehang Xu1, Zheng Zhou1, Shitu Chen 1, Quan Zhou1,4, Jinghao Sheng 5,6, Chi Luo7 ✉, Lisong Teng 1 ✉ and Weibin Wang 1 ✉  \n© The Author(s) 2026  \n|  |  |  |\n| --- | --- | --- |\n|  | BRAF-targeted therapy is a promising strategy for thyroid cancer. However, its efﬁcacy is limited by drug resistance. This study elucidates the role of fatty acid oxidation (FAO) in mediating adaptive resistance to BRAFV600E inhibition (BRAFi) in thyroid cancer. Through integrated transcriptomic and metabolomic analyses, we demonstrate that BRAFi by vemurafenib (PLX4032) signiﬁcantly enhances FAO in thyroid cancer cells. The pharmacological inhibition of FAO via thioridazine (Thio) synergizes with BRAFi to suppress tumor growth in vitro, in vivo and in a patient-derived organoid. Mechanistically, this metabolic shift is driven by the upregulation of PGC1α, which enhances FAO. The consequent increase in intracellular acetyl-CoA reprograms the histone H3K9 acetylation (H3K9ac) landscape, thereby epigenetically activating pro-survival genes such as RUNX1 . In addition, higher expression of RUNX1 correlates with poorer prognosis in thyroid cancer. Consistently, functional studies conﬁrm RUNX1’s oncogenic role, as its knockdown reduces cell proliferation, migration, and invasion. In conclusion, our work reveals a metabolic-epigenetic axis |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| underlying adaptive response to BRAFi and identiﬁes RUNX1 as a novel oncogene in thyroid cancer. |  |  |\n|  | Cell Death and Disease (2026)17:329; [https://doi.org/10.1038/s41419-026-08575-7](https://doi.org/10.1038/s41419-026-08575-7) |  |\n|  |  |  |\n\nINTRODUCTION  \nThyroid cancer, recognized as the most prevalent endocrine malignancy, has seen a sustained increase in global incidence over recent decades [1] . Although the majority of cases exhibit indolent clinical behavior, aggressive histologic subtypes, particularly poorly differentiated (PDTC) and anaplastic thyroid cancer (ATC), marked by rapid locoregional invasion and dismal median overall survival (8–12 months), persist as critical therapeutic challenges [2, 3] . BRAFV600E mutation is a driver oncogene for these patients, highlighting BRAF-targeted therapy as a cornerstone for managing advanced patients [4] . Nonetheless, BRAF-targeted agents achieve limited therapeutic efﬁcacy due to the emergence of drug resistance. Several studies have attempted to clarify how BRAFtargeted resistance occurs, including BRAF splicing variants, activation of the RTK pathway [5–8] . We previously demonstrated that autophagy activation and VCAM-1 (vascular cell adhesion molecule 1) upregulation constitute key mediators of cellular adaptive responses to BRAFV600E inhibition (BRAFi) [9, 10] . However, underlying mechanisms remain to be fully elucidated.  \nIn recent years, altered lipid metabolism has garnered signiﬁcant attention as a key contributor to tumor progression and drug resistance [11] . For instance, our analysis revealed that preoperative serum lipids can serve as novel predictors of thyroid  \ncancer patients’ survival outcomes [12] . Fatty acid oxidation (FAO) represents another lipid metabolic pathway closely associated with drug resistance. This metabolic process involves the catabolism of long-chain fatty acids, enables cancer cells, particularly those under pharmacological treatment or within nutrient-deprived tumor microenvironments, to maintain bioenergetic and redox homeostasis, thereby promoting survival [13–15] . While FAO has attracted growing interest, its speciﬁc role in thyroid cancer remains poorly characterized. Furthermore, although existing studies have established c","cbCaith6d2mekvhu","https://ap.wps.com/l/cbCaith6d2mekvhu","pdf",4354855,15,"English","# Introduction\n## Background on thyroid cancer and BRAFV600E targeted therapy\n## Role of fatty acid oxidation in drug resistance\n## Metabolism-epigenetic interplay and acetyl-CoA signaling","[{\"question\":\"How does BRAFV600E inhibition influence fatty acid oxidation in thyroid cancer?\",\"answer\":\"BRAFV600E inhibition with vemurafenib significantly enhances fatty acid oxidation (FAO) in thyroid cancer cells, as shown by integrated transcriptomic and metabolomic analyses.\"},{\"question\":\"What is the effect of pharmacologically inhibiting FAO during BRAFi treatment?\",\"answer\":\"FAO inhibition using thioridazine synergizes with BRAFV600E inhibition to suppress tumor growth in vitro, in vivo, and in patient-derived organoids.\"},{\"question\":\"How does increased acetyl-CoA connect metabolism to epigenetic activation of resistance genes?\",\"answer\":\"The metabolic shift increases intracellular acetyl-CoA, which reprograms the histone H3K9 acetylation (H3K9ac) landscape and epigenetically activates pro-survival genes such as RUNX1.\"}]","Fatty acid oxidation drives acetyl-CoA-dependent H3K9ac reprogramming to promote adaptive resistance to BRAFV600E inhibition in thyroid cancer | PDF",1790093686,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ba6096c12a4e0d51cd0a03bd113d3b6c.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0c6d6c479db5d4349b64686f41e93128.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8aa2b4e76de10db06f7560084a595584.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/41e6b5f16e075edc33237dde17ccf7f2.webp",980,1301]